苯磺酸左旋氨氯地平片治疗高血压的效果评价  

Evaluation of the effect of levamlodipine besylate tablets in the treatment of hypertension

作　　者：顾凯琳 GU Kai-lin(Community Health Service Station,Fushan New Area,Shibei District,Qingdao 266035,China)

机构地区：[1]青岛市市北区浮山新区街道社区卫生服务站,266035

出　　处：《中国现代药物应用》2025年第5期75-78,共4页Chinese Journal of Modern Drug Application

摘　　要：目的评价苯磺酸左旋氨氯地平片治疗高血压的效果。方法106例高血压患者,随机分为对照组(53例)、观察组(53例)。对照组给予硝苯地平治疗,观察组给予苯磺酸左旋氨氯地平片治疗。比较两组疗效,不良反应发生情况,治疗前后血压、血脂、血液流变学、血管内皮功能、炎症指标。结果观察组总有效率(96.23%)显著高于对照组(83.02%)(P<0.05)。治疗后,观察组舒张压(73.26±2.36)mm Hg(1 mm Hg=0.133 kPa)、收缩压(125.46±11.27)mm Hg、低密度脂蛋白胆固醇(LDL-C)(1.74±0.76)mmol/L、总胆固醇(TC)(4.40±0.93)mmol/L、甘油三酯(TG)(1.89±0.96)mmol/L均低于对照组的(79.18±2.40)mm Hg、(134.18±12.56)mm Hg、(2.15±0.82)mmol/L、(5.52±1.13)mmol/L、(2.74±1.21)mmol/L(P<0.05)。治疗后,观察组血浆粘度(2.05±0.31)mPa·s、纤维蛋白原(2.48±0.34)g/L、红细胞聚集指数(4.67±1.12)均低于对照组的(2.23±0.36)mPa·s、(3.23±0.36)g/L、(5.21±1.37)(P<0.05)。治疗后,观察组一氧化氮(NO)(35.71±8.32)μmol/L高于对照组的(30.33±8.21)μmol/L,内皮素-1(ET-1)(78.17±30.43)ng/L低于对照组的(94.52±29.62)ng/L(P<0.05)。(P<0.05)。治疗后,观察组超敏C反应蛋白(hs-CRP)(6.57±1.19)mg/L、肿瘤坏死因子-α(TNF-α)(36.68±3.75)pg/ml、白细胞介素-6(IL-6)(21.92±2.30)ng/L均低于对照组的(8.09±1.26)mg/L、(44.64±4.61)pg/ml、(34.64±4.61)ng/L(P<0.05)。观察组不良反应发生率(9.43%)低于对照组(28.30%)(P<0.05)。结论与硝苯地平相比,苯磺酸左旋氨氯地平片治疗高血压患者的疗效更佳,且具较高安全性。Objective To evaluate the effect of levamlodipine besylate tablets in the treatment of hypertension.Methods 106 patients with hypertension were randomly divided into a control group(53 cases)and an observation group(53 cases).The control group was treated with nifedipine,and the observation group was treated with levamlodipine besylate tablets.The efficacy,adverse reactions,blood pressure,blood lipid,hemorheology,vascular endothelial function and inflammation index before and after treatment were compared between the two groups.Results The total effective rate of the observation group(96.23%)was significantly higher than that of the control group(83.02%)(P<0.05).After treatment,the observation group had diastolic blood pressure of(73.26±2.36)mm Hg(1 mm Hg=0.133 kPa),systolic blood pressure of(125.46±11.27)mm Hg,low density lipoprotein cholesterol(LDL-C)of(1.74±0.76)mmol/L,total cholesterol(TC)of(4.40±0.93)mmol/L,and triglyceride(TG)of(1.89±0.96)mmol/L,which were lower than(79.18±2.40)mm Hg,(134.18±12.56)mm Hg,(2.15±0.82)mmol/L,(5.52±1.13)mmol/L,and(2.74±1.21)mmol/L in the control group(P<0.05).After treatment,the observation group had plasma viscosity of(2.05±0.31)mPa·s,fibrinogen of(2.48±0.34)g/L,and erythrocyte aggregation index of(4.67±1.12),which were lower than(2.23±0.36)mPa·s,(3.23±0.36)g/L,and(5.21±1.37)in the control group(P<0.05).After treatment,the observation group had a higher nitric oxide(NO)of(35.71±8.32)μmol/L than(30.33±8.21)μmol/L in the control group,and a lower endothelin-1(ET-1)of(78.17±30.43)ng/L than(94.52±29.62)ng/L in the control group(P<0.05).After treatment,the observation group had hypersensitive C-reactive protein(hs-CRP)of(6.57±1.19)mg/L,tumor necrosis factor-α(TNF-α)of(36.68±3.75)pg/ml,and interleukin-6(IL-6)of(21.92±2.30)ng/L,which were lower than(8.09±1.26)mg/L,(44.64±4.61)pg/ml,and(34.64±4.61)ng/L in the control group(P<0.05).The incidence of adverse reactions in the observation group(9.43%)was lower than that in the control group(28.30%)(P<0.05).Co

关 键 词：高血压 苯磺酸左旋氨氯地平片 疗效 安全性 硝苯地平 

分 类 号：R54[医药卫生—心血管疾病]